IGM Bio­sciences cuts 22% of work­force, ax­es hema­to­log­ic on­col­o­gy pro­gram

IGM Bio­sciences is not on­ly re­duc­ing its work­force by about 22%, but it is al­so ax­ing its clin­i­cal de­vel­op­ment pro­gram in hema­to­log­ic on­col­o­gy as well as an un­named tar­get­ed cy­tokine can­di­date.

The Cal­i­for­nia-based com­pa­ny said the changes would ex­tend its cash run­way in­to the sec­ond quar­ter of 2026, stretch­ing the orig­i­nal time­line of the sec­ond half of 2025. Ac­cord­ing to SEC fil­ings, IGM had 290 full-time em­ploy­ees as of Sept. 30.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER